The short answer
The type of magnesium product matters. An enalapril product document warns that antacids can reduce absorption of ACE inhibitors, which is relevant when magnesium is used as an antacid. That does not establish the same effect for every magnesium supplement, or prove harmful low blood pressure with ordinary supplement use.
What this answer covers
Oral magnesium supplements, magnesium-containing antacids or laxatives with oral enalapril. Identify the salt, elemental amount and purpose. Intravenous magnesium and magnesium present only as a tablet excipient are outside this scope.
- Supplement or preparation
- Magnesium
- Medication ingredient
- enalapril
Is an antacid different from a supplement?
Some magnesium products treat heartburn or constipation, while others are sold to supplement dietary intake. The UK enalapril document warns that antacids reduce ACE-inhibitor availability. It does not identify a particular magnesium salt or show that every magnesium tablet has this effect. Ask the pharmacist to check the exact product.
Should I automatically separate the doses?
The checked enalapril document does not give a tested spacing interval. Rules for magnesium with certain antibiotics or osteoporosis medicines cannot automatically be transferred to enalapril. A pharmacist can check the instructions for your medicine and antacid together; do not invent a schedule or alter the enalapril dose yourself.
Can magnesium itself cause low blood pressure?
Very large magnesium doses can cause toxicity, including low blood pressure, and kidney disease makes this more likely. Oral magnesium can also cause diarrhea. These are important product risks, but they do not establish that ordinary magnesium supplementation causes an additional enalapril interaction. More magnesium is not necessarily better.
When should I seek advice?
Arrange a review before using high-dose supplements or regular magnesium laxatives if you have kidney disease. Tell the prescriber about persistent diarrhea, dizziness or unusually low readings, because fluid loss can affect enalapril treatment. Marked weakness, fainting or breathing difficulty needs urgent medical assessment.
Evidence and practical considerations
Absorption & effectiveness
The type of magnesium product matters. An enalapril product document warns that antacids can reduce absorption of ACE inhibitors, which is relevant when magnesium is used as an antacid. That does not establish the same effect for every magnesium supplement, or prove harmful low blood pressure with ordinary supplement use.
- Exact scope
- Oral magnesium supplements, magnesium-containing antacids or laxatives with oral enalapril. Identify the salt, elemental amount and purpose. Intravenous magnesium and magnesium present only as a tablet excipient are outside this scope. with Enalapril, RxCUI 3827, IN. Oral enalapril maleate tablets are an explicitly identified salt formulation of enalapril in the label. This bridge applies to the labeled oral prodrug; injected enalaprilat, other ACE inhibitors and combination products are not assigned this evidence automatically.
- Medication form and route
- oral
- Timing or duration
- Limited to the exposure durations described in the sources; no untested duration or timing rule is inferred.
What remains uncertain
- The UK label precaution is class-worded and does not quantify enalapril-magnesium absorption or name a spacing interval. No direct exact-pair hypotension trial was identified. Magnesium toxicity and diarrhea are separate exposure-related concerns.
Factors that may matter: exact preparation and dose; baseline blood pressure; kidney function; diuretics and other medicines; dehydration.
Read the supporting source summaries
Source 1: regulatory prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed oral enalapril maleate for hypertension or heart failure.
Potassium products can substantially increase serum potassium; when indicated for documented low potassium, use cautiously with frequent testing. Dehydration and intensive diuretic treatment increase hypotension risk.
How this applies: The maleate formulation is explicitly identified as a salt of enalapril. Applies to oral enalapril, RxCUI 3827 IN; does not transfer to injected enalaprilat or another ACE inhibitor.
A drug label supports named warnings, not every botanical combination. Trial hyperkalemia rates are for enalapril treatment and do not quantify the incremental risk of potassium supplements. The inspected US label has no antacid-specific paragraph.
Source 2: manufacturer regulatory product information
riagenerics.com · Source check Sep 10, 2026
Population: Adults using the specified oral enalapril maleate tablets; interaction studies described as adult studies.
States that antacids decrease ACE-inhibitor bioavailability.
How this applies: A product-specific precaution can inform review of magnesium-containing antacids, but not a universal interaction for every magnesium form.
Class-worded label statement gives no enalapril-magnesium study, salt-specific effect size or exact spacing interval. Magnesium supplements are not all antacids. The inspected US label lacks this statement; omission does not refute it.
Source 3: government nutrient reference
ods.od.nih.gov · Source check Sep 10, 2026
Population: People using magnesium-containing supplements, antacids or laxatives.
Large doses can cause diarrhea; magnesium toxicity can cause hypotension and other serious effects. Impaired renal clearance increases toxicity risk.
How this applies: Supports differentiation of ordinary oral supplements, antacids and excessive magnesium exposure, not transfer from intravenous magnesium.
Supplement toxicity is not an enalapril-specific interaction. The nutrient summary does not establish an enalapril absorption effect or dose separation for all magnesium salts.
Research assessment: · Open full citations ↗
Side effects & toxicity
Harmful low blood pressure caused specifically by magnesium with enalapril has not been established. Magnesium toxicity and diarrhea at excessive doses remain separate safety concerns.
- Exact scope
- Oral magnesium supplements, magnesium-containing antacids or laxatives with oral enalapril. Identify the salt, elemental amount and purpose. Intravenous magnesium and magnesium present only as a tablet excipient are outside this scope. with Enalapril, RxCUI 3827, IN. Oral enalapril maleate tablets are an explicitly identified salt formulation of enalapril in the label. This bridge applies to the labeled oral prodrug; injected enalaprilat, other ACE inhibitors and combination products are not assigned this evidence automatically.
- Medication form and route
- oral
What remains uncertain
- Insufficient exact-pair evidence. NIH describes hypotension during magnesium toxicity and gastrointestinal fluid loss at high exposures; these are not proof of increased enalapril toxicity at ordinary supplement doses. Preserve renal-risk and dose boundaries.
Factors that may matter: excessive magnesium dose; impaired kidney function; dehydration.
Read the supporting source summaries
Source 1: government nutrient reference
ods.od.nih.gov · Source check Sep 10, 2026
Population: People using magnesium-containing supplements, antacids or laxatives.
Large doses can cause diarrhea; magnesium toxicity can cause hypotension and other serious effects. Impaired renal clearance increases toxicity risk.
How this applies: Supports differentiation of ordinary oral supplements, antacids and excessive magnesium exposure, not transfer from intravenous magnesium.
Supplement toxicity is not an enalapril-specific interaction. The nutrient summary does not establish an enalapril absorption effect or dose separation for all magnesium salts.
Source 2: regulatory prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed oral enalapril maleate for hypertension or heart failure.
Potassium products can substantially increase serum potassium; when indicated for documented low potassium, use cautiously with frequent testing. Dehydration and intensive diuretic treatment increase hypotension risk.
How this applies: The maleate formulation is explicitly identified as a salt of enalapril. Applies to oral enalapril, RxCUI 3827 IN; does not transfer to injected enalaprilat or another ACE inhibitor.
A drug label supports named warnings, not every botanical combination. Trial hyperkalemia rates are for enalapril treatment and do not quantify the incremental risk of potassium supplements. The inspected US label has no antacid-specific paragraph.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Original sources checked and a new article prepared, distinguishing the exact medicine and supplement preparation from related studies. No independent clinical review is recorded. | |
| Research summary published |
Article revision: 3775e999cebe98c0
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.